NCT02875028View on ClinicalTrials.gov

Vorapaxar in the Human Endotoxemia Model

PHASE4CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

June 30, 2016

Primary Completion Date

November 30, 2016

Study Completion Date

November 30, 2016

Conditions
Healthy Volunteers
Interventions
DRUG

Vorapaxar

10mg-20mg vorapaxar to achieve \>80% thrombin-receptor activated peptide-6 (TRAP) induced platelet inhibition

DRUG

Placebo

OTHER

LPS

2ng/kg Lipopolysaccharide as a bolus infusion

Trial Locations (1)

1090

Department of Clinical Pharmacology, Medical University of Vienna, Vienna

All Listed Sponsors
lead

Medical University of Vienna

OTHER

NCT02875028 - Vorapaxar in the Human Endotoxemia Model | Biotech Hunter | Biotech Hunter